spacer
home > white papers > Using Device Strategy to Drive R&D Productivity - Phillips-Medisize
WHITE PAPERS
logo_Phillips-Mk.jpg

Phillips-Medisize

phone +31 252 576 888
email eu_sales@phillipsmedisize.com
web http://www.phillipsmedisize.com
email Edisonstraat 1 Hillegom 2181 AB

Using Device Strategy to Drive R&D Productivity

Biopharmaceutical companies face sustained pressure from all sides to develop better products at lower costs, delivering value to patients, payers and shareholders. Healthcare costs are rising globally at an unsustainable level, putting the entire healthcare delivery system under pricing pressure. Biopharmaceutical companies have become popular targets, evidenced by increasing scrutiny on prescription medicine prices, even though spending on medicine accounts for only about ~10% of overall spend.
Using Device Strategy to Drive R&D Productivity
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

PCI Clinical Services Announces Launch of a Mobile App for its Comprehensive Customer Support Portal Webflow™

Philadelphia, USA – 15 November 2017. PCI has today announced the launch of a mobile application (app) to provide more convenient access to its client services online portal Webflow™. Webflow™ is a comprehensive customer support center which provides PCI clients real-time, 24/7 access to a wide range of reports and information regarding the status of their Clinical Trial supplies across all PCI Clinical Services sites in Europe and North America. The new free app, available on Android and Apple iOS, is designed to provide even more flexible access to the Webflow™ offering – enabling customers efficient and effective on demand supply chain management to meet the ever-changing requirements of global trials.  
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


Industry Events

14th World Advanced Therapies & Regenerative Medicine Congress 2018

16-18 May 2018, Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products).
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement